^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Xolremdi (mavorixafor)

    i
    Company:
    Abbisko, Norgine, X4 Pharma, taiba
    Drug class:
    CXCR4 antagonist
    Related drugs:
    Apply
    A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC (NCT05103917)
    Phase 1/2
    Abbisko Therapeutics Co, Ltd
    Enrolling by invitation
    Last update posted :
    11/02/2021
    Initiation :
    07/21/2021
    Primary completion :
    11/24/2022
    Completion :
    05/21/2023
    HER-2 • PGR
    |
    HER-2 negative • ER negative
    |
    Loqtorzi (toripalimab-tpzi) • Xolremdi (mavorixafor)